On the chart you can see the default numbers in dynamics for Ultragenyx Pharmaceutical Inc. (RARE). Companys revenue shows the average of 121.382 M which is 3.116 % gowth. The average gross profit for the whole period is 113.242 M which is 3.078 %. The average gross profit ratio is 0.588 %. The net income growth for the company last year performance is -0.142 % which equals -0.584 % % on average for the whole company history.,
Diving into the fiscal trajectory of Ultragenyx Pharmaceutical Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.035. In the realm of current assets, RARE clocks in at 732.184 in the reporting currency. A significant portion of these assets, precisely 777.11, is held in cash and short-term investments. This segment shows a change of -0.133% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 199.901, if any, in the reporting currency. This indicates a difference of 29.385% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 30.574 in the reporting currency. This figure signifies a year_over_year change of 0.366%. Shareholder value, as depicted by the total shareholder equity, is valued at 275.414 in the reporting currency. The year over year change in this aspect is -0.219%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 73.39, with an inventory valuation of 33.97, and goodwill valued at 44.41, if any. The total intangible assets, if present, are valued at 166.27.
The financial landscape of Ultragenyx Pharmaceutical Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of 0.010. The company recently extended its share capital by issuing 379.75, marking a difference of 17.143 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 2.38 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to 168000000.000 in the reporting currency. This is a shift of -1.576 from the previous year. In the same period, the company recorded 26.01, -2.55, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 8.39, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Ultragenyx Pharmaceutical Inc.'s revenue saw a change of 0.195% compared with the previous period. The gross profit of RARE is reported to be 389.04. The company's operating expenses are 958.25, showing a change of -2.610% from the last year. The expenses for depreciation and amortization are 26.01, which is a 1.735% change from the last accounting period. Operating expenses are reported to be 958.25, which shows a -2.610% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.123% year-over-year growth. The operating income is -569.21, which shows a -0.123% change when compared to the previous year. The change in the net income is -0.142%. The net income for the last year was -606.64.
